15 minutes | Sep 11th 2020

Veliparib Plus Carboplatin/Paclitaxel in BRCA-Mutated, HER2-Negative Advanced Breast Cancer

We’ll discuss the efficacy of a triplet combination therapy in BRCA-mutated, HER2-negative advanced breast cancer. Then, we’ll move on to a report that detailed multiorgan immunotherapy-related adverse events in patients treated with atezolizumab. Last, we’ll review the FDA’s approval of the RET-targeted therapy pralsetinib in patients with metastatic RET fusion–positive non–small cell lung cancer.

Coverage of stories discussed this week on ascopost.com:

Addition of Veliparib to Carboplatin/Paclitaxel in Previously Treated Patients With BRCA-Mutated Advanced Breast Cancer: BROCADE3 Trial

New Study Focuses on Multiorgan Immunotherapy-Related Adverse Events in Clinical Trials

FDA Approves Pralsetinib for Metastatic RET Fusion–Positive NSCLC

To listen to more podcasts from ASCO, visit asco.org/podcasts.

Play Next
Mark Played